PharmaLive: Genedata and Axxam Announce High Throughput Screening Data Analysis Collaboration
July 3rd, 2008 | by admin |BASEL, Switzerland and MILAN, Italy, July 3, 2008- Genedata and Axxam Announce High Throughput Screening Data Analysis Collaboration
Genedata, the leading provider of in silico solutions for the pharmaceutical and life science industries, and Axxam, a leading biotechnology research organization offering early-stage discovery research services for the life science industry, have signed a multi-year contract for the implementation of the Genedata Screener® data analysis and management platform into Axxam`s high throughput screening process.
With an increasing number of pharma and life science companies outsourcing entire stages of their research cycle, the contributions of contract research organizations (CROs) to drug development have never been more crucial. Faster development, earlier decisions on project failures, and higher approval success rates are becoming the norm. To continuously meet those high standards, Axxam relies on Genedata Screener. Screener’s high-quality, high-performance modular system rapidly and flexibly analyzes, integrates and manages all assay data and then combines it with chemical, pharmacological and in vivo information to support Axxam scientists in prioritizing compounds and identifying quality lead structures with the highest confidence. Screener`s open and scalable architecture integrates with existing infrastructures, which allows it to be tailored to specific discovery processes, maximizing value.
Dr. Stefan Lohmer, CEO of Axxam, said, ”Establishing flexible and efficient working practices to ensure client satisfaction is our top priority as a reputable service provider. Genedata`s consistently high performance and data quality along with their expertise and profound scientific knowledge enable us to meet that goal on a daily basis, with rigorous quality control covering every detail, as well as keeping to deadlines and budget terms. Thus, our focus extends beyond the actual license agreement with Genedata, towards a comprehensive, long-term partnership in high throughput screening.”
Dr. Othmar Pfannes, CEO of Genedata, stated, “We are proud to have met Axxam`s high selection standards. Genedata as leading research informatics provider and Axxam as ‘best-in-class’ contract research organization for life science discovery research are creating a powerful synergy here that lets us look with excitement to the future.“
Contact Genedata AG Public Relations Allison Kurz Phone +41 61 697 7378 Fax +41 61 697 7244 allison.kurz@genedata.com www.genedata.com
Axxam SpA Corp Communications Elisa Buzzi Phone +39 02 2105664 Fax +39 02 2105602 elisa.buzzi.eb@axxam.com www.axxam.com
Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The company offers expertise in research informatics combined with open and scalable computational solutions. Our product suites include Genedata Phylosopher® for integrating, structuring, and analyzing research data, Genedata Screener® for high throughput screening, high content screening analysis and hit-to-lead, and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin-off from Novartis, Genedata is headquartered in Basel, Switzerland, and has branches in Munich (Germany), Konstanz (Germany), Boston (USA), San Francisco (USA), and Tokyo (Japan). The company is also represented in Taiwan and Singapore. For more information visit: www.genedata.com.
Axxam is a science-driven biotechnology company, which offers early-stage discovery research services for the life science industry. The company applies its comprehensive from genes to leads activities to Discovery Services that we provide for customers and to internal Discovery Research. Activities include assay development, high-throughput screening (HTS) and compound profiling. A team of almost 70 qualified personnel is committed to advance the discovery projects of our partners. The scientific know-how of our team is built upon years of experience as part of the assay development group of the Bayer HealthCare, Research and Development organization prior to the late 2001 inauguration of Axxam as an independent private company. The growing list of our collaborations in the life science industry is recognition of our success in areas such as the pharmaceutical, agrichemical, fragrance, cosmetic, flavour, food and beverage branches. Axxam is a privately-owned company with offices and state-of-the-art laboratories located in the San Raffaele Biomedical Science Park, Milan. For more information visit: www.axxam.com.
Disclaimer The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
To download the PDF version of this press release, please go to www.genedata.com
To unsubscribe from the Genedata Media Distribution List, please contact communications@genedata.com
Genedata AG - Maulbeerstrasse 46 - 4016 Basel - Switzerland - Tel. +41 61 697 6099 - Fax +41 61 697 7244 www.genedata.com - communications@genedata.com
Stumble it!
